Orforglipron vs Semaglutide
First oral non-peptide GLP-1 receptor agonist for diabetes and obesity
The revolutionary once-weekly GLP-1 medication that helps your body feel full faster and longer, leading to significant weight loss while also protecting your heart—FDA approved and backed by some of the largest clinical trials in obesity medicine history.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Orforglipron
12–12 mg
Semaglutide
0.5–1 mg
Frequency
Orforglipron
Once daily
Semaglutide
Once weekly
Administration
Orforglipron
oral
Semaglutide
Subcutaneous injection
Cycle length
Orforglipron
Ongoing/indefinite
Semaglutide
Ongoing/indefinite
Onset speed
Orforglipron
Moderate (1-2 weeks)
Semaglutide
Moderate (1-2 weeks)
Evidence level
Orforglipron
Strong human trials (Phase 3 or FDA approved)
Semaglutide
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Weight Management
Blood Sugar Control
Cardiovascular Health
Weight Loss
Appetite Control
Heart Protection
Compound specifications
Orforglipron
Molecular formula
C48H48F2N10O5
Molecular weight
883.0 Da
Half-life
25-68 hours (dose-dependent; enables once-daily oral dosing)
Bioavailability
~79% oral bioavailability (food-independent)
CAS number
2212020-52-3
Semaglutide
Molecular formula
C187H291N45O59
Molecular weight
4113.58 g/mol
Half-life
Approximately 7 days (168 hours)
Bioavailability
89% (subcutaneous); 0.4-1% (oral, with absorption enhancer)
CAS number
910463-68-2
Dosing compared
Orforglipron
Oral
Lowest of three phase-3 maintenance doses
6 mg once daily
Once daily, any time of day · Lowest of three phase-3 maintenance doses
Lowest maintenance dose in the ATTAIN-1 phase-3 obesity trial; reached via gradual monthly titration from 1 mg [6]. Taken without food/water restrictions.
Maintained for 72-week trial duration
12 mg once daily
Once daily, any time of day · Maintained for 72-week trial duration
Mid-level maintenance dose in ATTAIN-1 phase-3 obesity trial [6].
Maintained for 72-week trial duration
36 mg once daily
Once daily, any time of day · Maintained for 72-week trial duration
Highest phase-3 dose; produced ~12.4% body-weight reduction at 72 weeks in ATTAIN-1 [6]. Investigational, not yet FDA-approved.
Semaglutide
Subcutaneous
4 weeks
0.25 mg
Once weekly · 4 weeks
This is the starter dose to help your body adjust. It does not lower blood sugar much on its own, so it is only used for the first 4 weeks before stepping up [5].
At least 4 weeks at each step
0.5-1 mg
Once weekly · At least 4 weeks at each step
After the starter month, the dose goes up to 0.5 mg, and can rise to 1 mg if more blood sugar control is needed. Wait at least 4 weeks before each increase [5].
Ongoing/maintenance
2-2.4 mg
Once weekly · Ongoing/maintenance
The highest weekly doses. 2 mg is the maximum for diabetes (Ozempic) [5]; up to 2.4 mg is used for weight management (Wegovy) after a slower titration.
Oral
30 days
3 mg
Once daily · 30 days
The pill form (Rybelsus) starts at 3 mg each morning for 30 days. Like the starter shot, this dose is for getting started and does not control blood sugar by itself. Take on an empty stomach with a small sip of water, 30 minutes before food or other pills [6].
30+ days
7 mg
Once daily · 30+ days
After the first 30 days, the dose increases to 7 mg once daily. This is the first dose that actively lowers blood sugar [6].
Ongoing/maintenance
14 mg
Once daily · Ongoing/maintenance
The highest pill dose, used if more blood sugar control is needed after at least 30 days at 7 mg [6].
Best suited for
Orforglipron
Oral GLP-1 receptor agonism without injection burden
Orforglipron is particularly well-suited for individuals focused on oral glp-1 receptor agonism without injection burden. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Weight management in obesity with or without type 2 diabetes
Orforglipron is particularly well-suited for individuals focused on weight management in obesity with or without type 2 diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Glycemic control in type 2 diabetes as add-on to metformin
Orforglipron is particularly well-suited for individuals focused on glycemic control in type 2 diabetes as add-on to metformin. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cardiovascular risk reduction through weight loss and metabolic improvements
Orforglipron is particularly well-suited for individuals focused on cardiovascular risk reduction through weight loss and metabolic improvements. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Semaglutide
People with Obesity Seeking Significant Weight Loss
If your BMI is 30 or higher (or 27+ with weight-related health conditions), semaglutide is currently one of the most effective non-surgical weight loss options available. [7] Clinical trials show average weight loss of 15% of body weight—that's 30+ pounds for someone starting at 200 pounds [1].
Those Who've Struggled with Diet and Exercise Alone
Semaglutide works by changing the biological signals that drive hunger and cravings. If you've tried to lose weight through willpower alone and found yourself constantly battling hunger, this medication addresses that underlying biology rather than just telling you to eat less [3][7][13].
People with Type 2 Diabetes Needing Better Control
Originally developed for diabetes, semaglutide excellently controls blood sugar while also promoting weight loss—addressing two major health concerns simultaneously. [3][5] It can often allow people to reduce or eliminate other diabetes medications [21].
Individuals at High Cardiovascular Risk
The SELECT trial proved that semaglutide reduces heart attacks, strokes, and cardiovascular death by 20% in people with obesity and existing heart disease—even without diabetes. It's one of the few weight loss medications proven to improve hard cardiovascular outcomes [2].
Side effects
Orforglipron
Common
- Nausea
- Constipation
- Diarrhea
- Vomiting
Uncommon
- Heart Rate Increase
Serious
- Pancreatitis Risk
Semaglutide
Common
- Nausea
- Constipation or Diarrhea
- Decreased Appetite
- Vomiting
Uncommon
- Gallbladder Problems
- Hair Loss (Telogen Effluvium)
Serious
- Pancreatitis
- Thyroid Tumors (Theoretical Risk)
Safety & evidence
Orforglipron
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Research compound
Safety overview
Orforglipron (MK-0731) completed Phase II trials for type 2 diabetes with favorable safety profile at oral doses of 10-40 mg daily. Gastrointestinal side effects (nausea, vomiting) occurred in 20-30% of subjects but were dose-dependent and generally mild. As a GLP-1 receptor agonist, risks include potential medullary thyroid carcinoma (black box warning category) and acute pancreatitis, requiring thyroid screening before treatment initiation and patient education on symptoms.
Contraindications
- Personal or family history of medullary thyroid carcinoma (GLP-1 class precaution)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to orforglipron or excipients
- History of pancreatitis (use with caution)
Semaglutide
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Semaglutide has been studied in over 20,000 participants across multiple large clinical trials, making it one of the most thoroughly researched weight loss medications available. [1][2][8][9][10] The FDA approved it after rigorous review of safety data. While GI side effects are common (especially early on), serious side effects are rare. [1][7] The SELECT trial showed it actually reduces cardiovascular events, adding a safety benefit beyond just weight loss [2].
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- History of serious allergic reaction to semaglutide
- Current or recent pancreatitis
- Pregnancy or planning to become pregnant
Which is right for you?
Choose Orforglipron if...
- Oral GLP-1 receptor agonism without injection burden
- Weight management in obesity with or without type 2 diabetes
- Glycemic control in type 2 diabetes as add-on to metformin
- Cardiovascular risk reduction through weight loss and metabolic improvements
Choose Semaglutide if...
- Significant weight loss
- Long-term weight management
- Cardiovascular risk reduction
- Blood sugar control